Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
Epigenetic pathways play a critical role in the initiation, progression, and metastasis of cancer. Over the past few decades, significant progress has been made in the development of targeted epigenetic modulators (e.g., inhibitors). However, epigenetic inhibitors have faced multiple challenges, inc...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-02-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383523003556 |
| _version_ | 1797341247015223296 |
|---|---|
| author | Xiaopeng Peng Zhihao Hu Limei Zeng Meizhu Zhang Congcong Xu Benyan Lu Chengpeng Tao Weiming Chen Wen Hou Kui Cheng Huichang Bi Wanyi Pan Jianjun Chen |
| author_facet | Xiaopeng Peng Zhihao Hu Limei Zeng Meizhu Zhang Congcong Xu Benyan Lu Chengpeng Tao Weiming Chen Wen Hou Kui Cheng Huichang Bi Wanyi Pan Jianjun Chen |
| author_sort | Xiaopeng Peng |
| collection | DOAJ |
| description | Epigenetic pathways play a critical role in the initiation, progression, and metastasis of cancer. Over the past few decades, significant progress has been made in the development of targeted epigenetic modulators (e.g., inhibitors). However, epigenetic inhibitors have faced multiple challenges, including limited clinical efficacy, toxicities, lack of subtype selectivity, and drug resistance. As a result, the design of new epigenetic modulators (e.g., degraders) such as PROTACs, molecular glue, and hydrophobic tagging (HyT) degraders has garnered significant attention from both academia and pharmaceutical industry, and numerous epigenetic degraders have been discovered in the past decade. In this review, we aim to provide an in-depth illustration of new degrading strategies (2017–2023) targeting epigenetic proteins for cancer therapy, focusing on the rational design, pharmacodynamics, pharmacokinetics, clinical status, and crystal structure information of these degraders. Importantly, we also provide deep insights into the potential challenges and corresponding remedies of this approach to drug design and development. Overall, we hope this review will offer a better mechanistic understanding and serve as a useful guide for the development of emerging epigenetic-targeting degraders. |
| first_indexed | 2024-03-08T10:16:10Z |
| format | Article |
| id | doaj.art-e9f9f251319d4fdf92ac3cb5930c5c4c |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-03-08T10:16:10Z |
| publishDate | 2024-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-e9f9f251319d4fdf92ac3cb5930c5c4c2024-01-29T04:15:11ZengElsevierActa Pharmaceutica Sinica B2211-38352024-02-01142533578Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologiesXiaopeng Peng0Zhihao Hu1Limei Zeng2Meizhu Zhang3Congcong Xu4Benyan Lu5Chengpeng Tao6Weiming Chen7Wen Hou8Kui Cheng9Huichang Bi10Wanyi Pan11Jianjun Chen12College of Pharmacy, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University, Ganzhou 314000, ChinaCollege of Pharmacy, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University, Ganzhou 314000, ChinaCollege of Basic Medicine, Gannan Medical University, Ganzhou 314000, ChinaCollege of Pharmacy, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University, Ganzhou 314000, ChinaCollege of Pharmacy, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University, Ganzhou 314000, ChinaCollege of Pharmacy, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University, Ganzhou 314000, ChinaCollege of Pharmacy, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University, Ganzhou 314000, ChinaCollege of Pharmacy, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University, Ganzhou 314000, ChinaCollege of Pharmacy, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University, Ganzhou 314000, ChinaGuangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; Corresponding authors.Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; Corresponding authors.College of Pharmacy, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University, Ganzhou 314000, China; Corresponding authors.Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; Corresponding authors.Epigenetic pathways play a critical role in the initiation, progression, and metastasis of cancer. Over the past few decades, significant progress has been made in the development of targeted epigenetic modulators (e.g., inhibitors). However, epigenetic inhibitors have faced multiple challenges, including limited clinical efficacy, toxicities, lack of subtype selectivity, and drug resistance. As a result, the design of new epigenetic modulators (e.g., degraders) such as PROTACs, molecular glue, and hydrophobic tagging (HyT) degraders has garnered significant attention from both academia and pharmaceutical industry, and numerous epigenetic degraders have been discovered in the past decade. In this review, we aim to provide an in-depth illustration of new degrading strategies (2017–2023) targeting epigenetic proteins for cancer therapy, focusing on the rational design, pharmacodynamics, pharmacokinetics, clinical status, and crystal structure information of these degraders. Importantly, we also provide deep insights into the potential challenges and corresponding remedies of this approach to drug design and development. Overall, we hope this review will offer a better mechanistic understanding and serve as a useful guide for the development of emerging epigenetic-targeting degraders.http://www.sciencedirect.com/science/article/pii/S2211383523003556EpigeneticDegraderPROTACMolecular glueHydrophobic tagging |
| spellingShingle | Xiaopeng Peng Zhihao Hu Limei Zeng Meizhu Zhang Congcong Xu Benyan Lu Chengpeng Tao Weiming Chen Wen Hou Kui Cheng Huichang Bi Wanyi Pan Jianjun Chen Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies Acta Pharmaceutica Sinica B Epigenetic Degrader PROTAC Molecular glue Hydrophobic tagging |
| title | Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies |
| title_full | Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies |
| title_fullStr | Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies |
| title_full_unstemmed | Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies |
| title_short | Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies |
| title_sort | overview of epigenetic degraders based on protac molecular glue and hydrophobic tagging technologies |
| topic | Epigenetic Degrader PROTAC Molecular glue Hydrophobic tagging |
| url | http://www.sciencedirect.com/science/article/pii/S2211383523003556 |
| work_keys_str_mv | AT xiaopengpeng overviewofepigeneticdegradersbasedonprotacmolecularglueandhydrophobictaggingtechnologies AT zhihaohu overviewofepigeneticdegradersbasedonprotacmolecularglueandhydrophobictaggingtechnologies AT limeizeng overviewofepigeneticdegradersbasedonprotacmolecularglueandhydrophobictaggingtechnologies AT meizhuzhang overviewofepigeneticdegradersbasedonprotacmolecularglueandhydrophobictaggingtechnologies AT congcongxu overviewofepigeneticdegradersbasedonprotacmolecularglueandhydrophobictaggingtechnologies AT benyanlu overviewofepigeneticdegradersbasedonprotacmolecularglueandhydrophobictaggingtechnologies AT chengpengtao overviewofepigeneticdegradersbasedonprotacmolecularglueandhydrophobictaggingtechnologies AT weimingchen overviewofepigeneticdegradersbasedonprotacmolecularglueandhydrophobictaggingtechnologies AT wenhou overviewofepigeneticdegradersbasedonprotacmolecularglueandhydrophobictaggingtechnologies AT kuicheng overviewofepigeneticdegradersbasedonprotacmolecularglueandhydrophobictaggingtechnologies AT huichangbi overviewofepigeneticdegradersbasedonprotacmolecularglueandhydrophobictaggingtechnologies AT wanyipan overviewofepigeneticdegradersbasedonprotacmolecularglueandhydrophobictaggingtechnologies AT jianjunchen overviewofepigeneticdegradersbasedonprotacmolecularglueandhydrophobictaggingtechnologies |